Zomedica Corp Financials
This page shows Zomedica Corp (ZOMDF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Zomedica Corp has an operating margin of -263.4%, meaning the company retains $-263 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -187.1% the prior year.
Zomedica Corp's revenue surged 17.4% year-over-year to $32.0M, reflecting rapid business expansion. This strong growth earns a score of 62/100.
Zomedica Corp carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.78, Zomedica Corp holds $6.78 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Zomedica Corp generated -$17.6M in operating cash flow, capex of $567K consumed most of it, leaving -$18.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Zomedica Corp generates a -70.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -24.0% the prior year.
Zomedica Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Zomedica Corp generates $0.22 in operating cash flow (-$17.6M OCF vs -$81.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Zomedica Corp generated $32.0M in revenue in fiscal year 2025. This represents an increase of 17.4% from the prior year.
Zomedica Corp's EBITDA was -$76.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 77.4% from the prior year.
Zomedica Corp reported -$81.9M in net income in fiscal year 2025. This represents a decrease of 74.2% from the prior year.
Zomedica Corp earned $-0.08 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 60.0% from the prior year.
Cash & Balance Sheet
Zomedica Corp generated -$18.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 36.8% from the prior year.
Zomedica Corp held $9.0M in cash against $0 in long-term debt as of fiscal year 2025.
Zomedica Corp had 980M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Zomedica Corp's gross margin was 67.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.3 percentage points from the prior year.
Zomedica Corp's operating margin was -263.4% in fiscal year 2025, reflecting core business profitability. This is down 76.3 percentage points from the prior year.
Zomedica Corp's net profit margin was -255.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 83.4 percentage points from the prior year.
Zomedica Corp's ROE was -70.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 46.9 percentage points from the prior year.
Capital Allocation
Zomedica Corp invested $7.2M in research and development in fiscal year 2025. This represents a decrease of 1.4% from the prior year.
Zomedica Corp invested $567K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.1% from the prior year.
ZOMDF Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5M+29.4% | $8.1M+16.2% | $7.0M+7.1% | $6.5M-17.7% | $7.9M+12.8% | $7.0M+14.1% | $6.1M-2.1% | $6.3M |
| Cost of Revenue | $3.3M+24.1% | $2.7M+15.7% | $2.3M+9.8% | $2.1M-10.8% | $2.3M+21.2% | $1.9M+9.5% | $1.8M-17.5% | $2.1M |
| Gross Profit | $7.2M+31.9% | $5.4M+16.5% | $4.7M+5.9% | $4.4M-20.6% | $5.5M+9.6% | $5.1M+16.0% | $4.4M+6.0% | $4.1M |
| R&D Expenses | $1.6M-7.9% | $1.8M-5.4% | $1.9M+1.8% | $1.9M-13.7% | $2.1M+16.3% | $1.8M+22.5% | $1.5M-15.0% | $1.8M |
| SG&A Expenses | $6.2M+4.6% | $5.9M-4.3% | $6.2M-1.6% | $6.3M-0.4% | $6.3M-7.0% | $6.8M-15.2% | $8.0M-7.5% | $8.6M |
| Operating Income | -$5.2M+21.8% | -$6.6M+17.8% | -$8.0M+87.6% | -$64.5M-691.0% | -$8.2M-9.7% | -$7.4M+70.3% | -$25.1M-141.4% | -$10.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$214K-1026.3% | -$19K-258.3% | $12K+121.1% | -$57K+74.2% | -$221K-718.5% | -$27K+81.1% | -$143K+13.9% | -$166K |
| Net Income | -$4.5M+26.0% | -$6.1M+17.3% | -$7.4M+88.4% | -$63.8M-787.0% | -$7.2M-7.4% | -$6.7M+72.0% | -$23.9M-161.3% | -$9.2M |
| EPS (Diluted) | N/A | $-0.010.0% | $-0.01+85.7% | $-0.07 | N/A | $-0.01+50.0% | $-0.02-100.0% | $-0.01 |
ZOMDF Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $127.0M-3.0% | $130.9M-4.1% | $136.5M-4.6% | $143.0M-31.0% | $207.4M-3.2% | $214.1M-2.6% | $219.9M-9.8% | $243.7M |
| Current Assets | $64.0M-1.0% | $64.7M-5.7% | $68.6M-6.3% | $73.2M-10.5% | $81.8M-6.3% | $87.3M-2.2% | $89.2M-3.1% | $92.1M |
| Cash & Equivalents | $9.0M+20.3% | $7.5M-7.8% | $8.1M-8.0% | $8.8M+25.9% | $7.0M-28.0% | $9.7M+22.8% | $7.9M-27.4% | $10.9M |
| Inventory | $5.5M+0.4% | $5.5M-2.6% | $5.7M+5.9% | $5.4M+5.9% | $5.1M-6.8% | $5.4M-1.4% | $5.5M+8.8% | $5.1M |
| Accounts Receivable | $3.0M-4.2% | $3.1M+36.9% | $2.3M+46.4% | $1.6M-35.2% | $2.4M+37.7% | $1.8M+27.2% | $1.4M-16.1% | $1.6M |
| Goodwill | $0 | $0 | $0 | N/A | $45.6M0.0% | $45.6M0.0% | $45.6M-26.0% | $61.6M |
| Total Liabilities | $11.6M+3.8% | $11.2M+0.9% | $11.1M+5.4% | $10.5M-9.8% | $11.7M+3.8% | $11.3M+1.0% | $11.2M-5.4% | $11.8M |
| Current Liabilities | $9.4M+12.1% | $8.4M+3.8% | $8.1M+9.8% | $7.4M-20.6% | $9.3M+15.7% | $8.1M+2.9% | $7.8M-2.2% | $8.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $115.4M-3.6% | $119.7M-4.5% | $125.4M-5.4% | $132.4M-32.3% | $195.7M-3.5% | $202.8M-2.8% | $208.7M-10.0% | $231.9M |
| Retained Earnings | -$299.8M-1.5% | -$295.2M-2.1% | -$289.1M-2.6% | -$281.7M-29.3% | -$217.9M-3.4% | -$210.7M-3.3% | -$204.0M-13.3% | -$180.1M |
ZOMDF Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$899K+80.7% | -$4.7M+14.4% | -$5.4M+18.1% | -$6.6M-46.9% | -$4.5M+5.7% | -$4.8M+28.6% | -$6.7M+11.5% | -$7.6M |
| Capital Expenditures | $107K+148.8% | $43K-68.6% | $137K-51.1% | $280K-51.3% | $575K-46.7% | $1.1M-11.9% | $1.2M-47.6% | $2.3M |
| Free Cash Flow | -$1.0M+78.6% | -$4.7M+15.7% | -$5.6M+19.5% | -$6.9M-35.8% | -$5.1M+13.2% | -$5.9M+26.0% | -$7.9M+20.0% | -$9.9M |
| Investing Cash Flow | $2.4M-39.4% | $4.0M-13.6% | $4.7M-44.3% | $8.4M+338.7% | $1.9M-70.7% | $6.5M+73.4% | $3.8M-32.9% | $5.6M |
| Financing Cash Flow | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZOMDF Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.5%+1.3pp | 67.2%+0.1pp | 67.0%-0.8pp | 67.8%-2.5pp | 70.3%-2.0pp | 72.3%+1.2pp | 71.2%+5.4pp | 65.8% |
| Operating Margin | -49.3%+32.3pp | -81.6%+33.8pp | -115.4%+877.7pp | -993.1%-889.7pp | -103.4%+3.0pp | -106.3%+302.5pp | -408.9%-243.0pp | -165.9% |
| Net Margin | -43.3%+32.4pp | -75.6%+30.6pp | -106.2%+875.5pp | -981.7%-890.6pp | -91.1%+4.6pp | -95.7%+294.6pp | -390.3%-244.1pp | -146.3% |
| Return on Equity | -3.9%+1.2pp | -5.1%+0.8pp | -5.9%+42.3pp | -48.2%-44.5pp | -3.7%-0.4pp | -3.3%+8.2pp | -11.5%-7.5pp | -4.0% |
| Return on Assets | -3.6%+1.1pp | -4.7%+0.7pp | -5.4%+39.2pp | -44.6%-41.1pp | -3.5%-0.3pp | -3.1%+7.7pp | -10.9%-7.1pp | -3.8% |
| Current Ratio | 6.78-0.9 | 7.67-0.8 | 8.44-1.4 | 9.89+1.1 | 8.76-2.1 | 10.82-0.6 | 11.39-0.1 | 11.50 |
| Debt-to-Equity | 0.100.0 | 0.090.0 | 0.090.0 | 0.08+0.0 | 0.060.0 | 0.060.0 | 0.050.0 | 0.05 |
| FCF Margin | -9.6%+48.5pp | -58.1%+22.0pp | -80.1%+26.5pp | -106.6%-42.0pp | -64.6%+19.4pp | -84.0%+45.6pp | -129.6%+28.9pp | -158.5% |
Similar Companies
Frequently Asked Questions
What is Zomedica Corp's annual revenue?
Zomedica Corp (ZOMDF) reported $32.0M in total revenue for fiscal year 2025. This represents a 17.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Zomedica Corp's revenue growing?
Zomedica Corp (ZOMDF) revenue grew by 17.4% year-over-year, from $27.3M to $32.0M in fiscal year 2025.
Is Zomedica Corp profitable?
No, Zomedica Corp (ZOMDF) reported a net income of -$81.9M in fiscal year 2025, with a net profit margin of -255.6%.
What is Zomedica Corp's EBITDA?
Zomedica Corp (ZOMDF) had EBITDA of -$76.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Zomedica Corp's gross margin?
Zomedica Corp (ZOMDF) had a gross margin of 67.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zomedica Corp's operating margin?
Zomedica Corp (ZOMDF) had an operating margin of -263.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Zomedica Corp's net profit margin?
Zomedica Corp (ZOMDF) had a net profit margin of -255.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Zomedica Corp's return on equity (ROE)?
Zomedica Corp (ZOMDF) has a return on equity of -70.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Zomedica Corp's free cash flow?
Zomedica Corp (ZOMDF) generated -$18.2M in free cash flow during fiscal year 2025. This represents a 36.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Zomedica Corp's operating cash flow?
Zomedica Corp (ZOMDF) generated -$17.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Zomedica Corp's total assets?
Zomedica Corp (ZOMDF) had $127.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Zomedica Corp's capital expenditures?
Zomedica Corp (ZOMDF) invested $567K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Zomedica Corp spend on research and development?
Zomedica Corp (ZOMDF) invested $7.2M in research and development during fiscal year 2025.
What is Zomedica Corp's current ratio?
Zomedica Corp (ZOMDF) had a current ratio of 6.78 as of fiscal year 2025, which is generally considered healthy.
What is Zomedica Corp's debt-to-equity ratio?
Zomedica Corp (ZOMDF) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zomedica Corp's return on assets (ROA)?
Zomedica Corp (ZOMDF) had a return on assets of -64.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Zomedica Corp's cash runway?
Based on fiscal year 2025 data, Zomedica Corp (ZOMDF) had $9.0M in cash against an annual operating cash burn of $17.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Zomedica Corp's Piotroski F-Score?
Zomedica Corp (ZOMDF) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Zomedica Corp's earnings high quality?
Zomedica Corp (ZOMDF) has an earnings quality ratio of 0.22x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Zomedica Corp?
Zomedica Corp (ZOMDF) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.